Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 8 (4) |
| Completed vs Stopped Early | 5 / 2 (13.3%) |
| Median Closed Actual Enrollment | 13 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Karmanos Cancer Institute | Detroit, MI | 8 |
| Wayne State University/Karmanos Cancer Institute | Detroit, MI | 4 |
| Barbara Ann Karmanos Cancer Institute | Detroit, MI | 3 |
Explore interactive annual charts and M&A subsidiary rollups in the Barbara Ann Karmanos Cancer Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.